Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
The International Journal of Biostatistics
|
October 24, 2012
A reproducing kernel-based spatial model in poisson regressions
Hongmei Zhang, Jianjun Gan
Bayesian Analysis
|
March 13, 2026
A Two-Component <i>G</i>-Prior for Variable Selection
Hongmei Zhang, Xianzheng Huang, Jianjun Gan, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults
Kimberly K Adkison, Lori S Jones, Yu Lou, et al.
Clinical Pharmacology in Drug Development
|
June 20, 2020
A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses
Mark Johnson, Roxanne C Jewell, Jianjun Gan, et al.
Pharmacotherapy
|
April 5, 2013
Effect of intravenous zanamivir on cardiac repolarization
Yu Lou, Jianjun Gan, Amanda Peppercorn, et al.
International Journal of General Medicine
|
September 3, 2011
Adjusting wheal size measures to correct atopy misclassification
Hongmei Zhang, Wilfried Karmaus, Jianjun Gan, et al.
The Science of the Total Environment
|
April 27, 2024
Biogeographic effects shape soil bacterial communities across intertidal zones on island beaches through regulating soil properties
Mingshan Xu, Xiaodong Yang, Jie Shao, et al.
Journal of Clinical Pharmacology
|
April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment
Kimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects
David A Wilfret, Jill Walker, Christian Voitenleitner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
Edwin DeJesus, Sara Harward, Roxanne C Jewell, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
The International Journal of Biostatistics
|
October 24, 2012
A reproducing kernel-based spatial model in poisson regressions
Hongmei Zhang, Jianjun Gan
Bayesian Analysis
|
March 13, 2026
A Two-Component <i>G</i>-Prior for Variable Selection
Hongmei Zhang, Xianzheng Huang, Jianjun Gan, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults
Kimberly K Adkison, Lori S Jones, Yu Lou, et al.
Clinical Pharmacology in Drug Development
|
June 20, 2020
A Phase 1 Study to Assess the Relative Bioavailability, Food Effect, and Safety of a Tablet Formulation of GSK2838232, a Novel HIV Maturation Inhibitor in Healthy Participants After Single and Repeated Doses
Mark Johnson, Roxanne C Jewell, Jianjun Gan, et al.
Pharmacotherapy
|
April 5, 2013
Effect of intravenous zanamivir on cardiac repolarization
Yu Lou, Jianjun Gan, Amanda Peppercorn, et al.
International Journal of General Medicine
|
September 3, 2011
Adjusting wheal size measures to correct atopy misclassification
Hongmei Zhang, Wilfried Karmaus, Jianjun Gan, et al.
The Science of the Total Environment
|
April 27, 2024
Biogeographic effects shape soil bacterial communities across intertidal zones on island beaches through regulating soil properties
Mingshan Xu, Xiaodong Yang, Jie Shao, et al.
Journal of Clinical Pharmacology
|
April 11, 2015
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment
Kimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects
David A Wilfret, Jill Walker, Christian Voitenleitner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
Edwin DeJesus, Sara Harward, Roxanne C Jewell, et al.
Page
of 2